Published in PLoS One on September 23, 2013
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
T cell-independent antigens type 2. Annu Rev Immunol (1995) 4.62
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood (2003) 2.70
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
B lymphocyte dysfunctions in HIV infection. Curr HIV Res (2004) 2.07
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology (2007) 1.84
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
Glycan microarrays for decoding the glycome. Annu Rev Biochem (2011) 1.81
High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl (2006) 1.78
T cell independent antigens. Curr Opin Immunol (1995) 1.78
Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med (2007) 1.76
Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res (2008) 1.73
Structure and function of natural antibodies. Curr Top Microbiol Immunol (1996) 1.72
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res (2009) 1.61
Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol (2011) 1.58
Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol (2009) 1.56
Glycan arrays: recent advances and future challenges. Curr Opin Chem Biol (2009) 1.52
Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J Proteome Res (2009) 1.45
Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology (2010) 1.39
Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res (2009) 1.39
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35
Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol (2001) 1.31
Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1990) 1.30
Glycoconjugate microarray based on an evanescent-field fluorescence-assisted detection principle for investigation of glycan-binding proteins. Glycobiology (2008) 1.25
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta (2008) 1.19
A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology (2003) 1.16
Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J Virol (1991) 1.11
Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis (2009) 1.08
Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology (2009) 1.06
An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol (1992) 1.06
Human b1 cell frequency: isolation and analysis of human b1 cells. Front Immunol (2012) 1.00
Serum antibody screening by surface plasmon resonance using a natural glycan microarray. Glycoconj J (2008) 1.00
Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines (2008) 1.00
A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res (2010) 1.00
Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta (2012) 0.94
Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systems. J Clin Microbiol (1985) 0.93
Construction and use of glycan microarrays. Curr Protoc Chem Biol (2010) 0.93
Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop. Arch Virol (1996) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol (2010) 0.90
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology (2011) 0.89
Hyperimmunoglobulinemia and rate of HIV type 1 infection progression. AIDS Res Hum Retroviruses (2004) 0.88
Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One (2012) 0.88
Multiplex suspension array for human anti-carbohydrate antibody profiling. Analyst (2010) 0.87
A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. Chem Biol (2012) 0.87
Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteomics Clin Appl (2010) 0.87
Random glycopeptide bead libraries for seromic biomarker discovery. J Proteome Res (2010) 0.86
Multidimensional glycan arrays for enhanced antibody profiling. Mol Biosyst (2010) 0.86
Printed glycan array: antibodies as probed in undiluted serum and effects of dilution. Glycoconj J (2012) 0.86
Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconj J (2010) 0.84
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One (2011) 0.83
Polysaccharide microarrays with a CMOS based signal detection unit. Biosens Bioelectron (2010) 0.80
Jacalin, a lectin interacting with O-linked sugars and mediating protection of CD4+ cells against HIV-1, binds to the external envelope glycoprotein gp120. Immunol Lett (1996) 0.80
Quantitation of serum immunoglobulins G, M, and A in the rhesus monkey (M. mulatta) using human monospecific antisera in the enzyme-linked immunosorbent assay: developmental aspects. J Med Primatol (1991) 0.78
A sensitive mapping strategy for monitoring the reproducibility of glycan processing in an HIV vaccine, RGP-160, expressed in a mammalian cell line. Glycoconj J (2000) 0.76
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol (2009) 1.93
High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology (2007) 1.84
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl (2006) 1.78
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Glycan arrays: recent advances and future challenges. Curr Opin Chem Biol (2009) 1.52
Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J Proteome Res (2009) 1.45
Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res (2009) 1.39
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26
Carbohydrate microarrays. Chem Soc Rev (2012) 1.25
Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem (2005) 1.24
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol (2006) 1.22
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr (2006) 1.21
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine (2011) 1.16
A simple strategy for the creation of a recombinant lectin microarray. Mol Biosyst (2008) 1.16
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13
A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines (2004) 1.11
TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol (2011) 1.11
Cross-platform comparison of glycan microarray formats. Glycobiology (2014) 1.08
Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther (2009) 1.07
Adenoviruses as vectors for HIV vaccines. AIDS Rev (2003) 1.04
Mechanistic studies and methods to prevent aglycon transfer of thioglycosides. J Am Chem Soc (2006) 1.03
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol (2012) 0.99
Application of carbohydrate array technology to antigen discovery and vaccine development. Expert Rev Vaccines (2007) 0.99
Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine (2003) 0.99
Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs (2007) 0.98
An array-based method to identify multivalent inhibitors. J Am Chem Soc (2010) 0.96
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol (2010) 0.93
Construction and use of glycan microarrays. Curr Protoc Chem Biol (2010) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Enhanced epimerization of glycosylated amino acids during solid-phase peptide synthesis. J Am Chem Soc (2012) 0.91
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology (2011) 0.91
Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res (2013) 0.90
Modifications of glycans: biological significance and therapeutic opportunities. ACS Chem Biol (2012) 0.90
GalNAcalpha1-3Gal, a new prognostic marker for cervical cancer. Int J Cancer (2010) 0.89
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology (2011) 0.89
NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol (2012) 0.89
Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine (2006) 0.88
Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology (2005) 0.87
Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteomics Clin Appl (2010) 0.87
Multidimensional glycan arrays for enhanced antibody profiling. Mol Biosyst (2010) 0.86
Boosting immunity to small tumor-associated carbohydrates with bacteriophage qβ capsids. ACS Chem Biol (2013) 0.86
Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens. Bioconjug Chem (2012) 0.86
Effects of hapten density on the induced antibody repertoire. Chembiochem (2010) 0.86
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol (2011) 0.86
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85
Recognition of the Thomsen-Friedenreich pancarcinoma carbohydrate antigen by a lamprey variable lymphocyte receptor. J Biol Chem (2013) 0.85
Sugar-binding proteins from fish: selection of high affinity "lambodies" that recognize biomedically relevant glycans. ACS Chem Biol (2012) 0.85
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine (2011) 0.84
Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem (2012) 0.83
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology (2013) 0.83
Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. AIDS Res Hum Retroviruses (2011) 0.83
Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res Hum Retroviruses (2004) 0.83
Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology (2013) 0.83
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J Virol (2002) 0.82
Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS (2006) 0.82
Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine (2011) 0.81
Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol (2002) 0.81
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol (2005) 0.81
Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine (2010) 0.80
Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas. Stem Cells Dev (2010) 0.80
Constitutive expression and regulation of rat complement factor H in primary cultures of hepatocytes, Kupffer cells, and two hepatoma cell lines. Lab Invest (2002) 0.80
Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology (2002) 0.79
MAb L9E10 to blood group H2 antigen binds to colon cancer stem cells and inhibits tumor cell migration and invasion. Hybridoma (Larchmt) (2010) 0.79
Live recombinant vectors for AIDS vaccine development. Curr Mol Med (2003) 0.79